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Abstract
Hypoluteoidism in the bitch is described as a reproductive condition in which insufficient
levels of endogenous progesterone are present resulting in failure to maintain a functional
secretory endometrium. This condition can prevent normal embryo implantation, development,
and ultimately end in pregnancy loss. Hypoluteoidism in the bitch is a rising concern in small
animal theriogenology and current medical therapies available to veterinarians are limited. The
aim of this study was to determine the pharmacokinetics (PK) of intravaginally (Crinone®,
Serono Laboratories, Norwell, MA) and orally delivered micronized progesterone (Prometrium®,
Solvay Pharmaceuticals, Inc., Marietta, GA) in the bitch. We hypothesized that both vaginal and
oral treatments would result in a dose-dependent increase in concentrations of plasma
progesterone. We further hypothesized that oral dosing of micronized progesterone would result
in greater, sustained plasma progesterone than those recorded in bitches treated with intravaginal
(IVa) micronized progesterone gel. Eight adult sexually intact bitches in anestrus were arranged
in a 4x4 Latin square cross over experimental design. Each subject rotated through four different
progesterone treatment groups with a minimum seven day-wash out period between treatments:
100 mg oral micronized progesterone, 200 mg oral micronized progesterone, 45 mg intravaginal
micronized progesterone and 90 mg intravaginal micronized progesterone. Blood samples from
each subject were obtained at time points 0, 0.5, 2, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours
following one initial dosing of each treatment. Concentrations of plasma progesterone were
determined by RIA (ImmuChem Double Antibody, 125I RIA Kit, MP Biomedicals, Costa Mesa,
CA). Pharmacokinetic analysis was carried out using commercially available software (Phoenix
WinNonlin 6.4, Certara Inc., Princeton, NJ). One-compartmental (intravaginal) and noncompartmental (oral administration) modeling were performed to analyze data using the mean
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concentrations for each dosing to calculate the area under the curve (AUC), maximum plasma
concentration (Cmax), time elapsed to reach Cmax (Tmax), and elimination half-life ( t1/2).
Results for the 100 mg and 200 mg oral doses and 45 mg and 90 mg IVA doses were as
follows: AUC, 30.86, 187.96, 90.64, and 226.68 ng.h.mL-1, respectively; Cmax, 13.47, 169, 8.68,
and 13.24 ng.mL-1, respectively; Tmax, 0.5, 0.5, 0.84, and 1.67 hr, respectively, and half-life,
5.87, 6.76, 6.6, and 10.65 hr, respectively.
Micronized progesterone was readily absorbed in bitches when administered either orally
or intravaginally. Contrary to our initial hypothesis, micronized progesterone exposure over time,
as indicated by the area under the curve, was greater when intravaginal micronized progesterone
was used. The ability of intravaginal preparations of micronized progesterone to induce sustained
progesterone exposure may provide an alternative strategy for treating pregnant dogs whenever
hypoluteoidism is being suspected.
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Chapter 1. Introduction and Literature Review
1.1 Canine Reproductive Cycle and Breeding
In veterinary medicine, it is important that the general practitioner develops a sound
understanding of reproductive physiology and endocrinology. The reproductive system not only
plays a major role in animal breeding, but its dysfunction can also contribute to the development
of several endocrinopathies. The domestic canine (Canis familiaris) reproductive cycle has been
well described in scientific literature (Heape, 1900). It involves four stages: proestrus, estrus,
diestrus, and anestrus. Most dogs will typically have two reproductive cycles per year; however,
there have been reports of some breed variation, such as the African basenji dog, displaying only
one reproductive cycle annually (Fuller, 1956).
Determining at what specific age to breed a bitch can be difficult for both the practicing
veterinarian and the owner. It is recommended to perform a bitch’s first breeding after at least
one complete normal reproductive cycle (Feldman and Nelson, 2004). Factors that influence the
start of a dog’s first reproductive cycle include breed, size, and seasonal patterns (Feldman and
Nelson, 2004). It is also not uncommon for owners to overlook the bitch’s first cycle, as result of
a reproductive condition called silent heat. This term is often used to describe the loss or
decrease of clinical signs usually associated with normal cycling in the bitch, such as swelling of
the vulva, vaginal bleeding, male attraction, and changes in behavior (Concannon, 1980).
Determining what phase of the reproductive cycle a bitch is in can also be challenging. It is
advised to use a multi-modal approach incorporating a variety of clinical techniques to achieve
this goal. Common procedures performed to determine the reproductive cycle stages include
vaginal cytology, blood hormonal assays (i.e., plasma progesterone, luteinizing hormone,
estrogen), and thorough physical examination of the reproductive organs and associated
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structures. The reproductive cycle begins with the onset of the proestrus. Clinically, vaginal
bleeding, vulva enlargement, and attraction of males due to pheromone secretion are indicative
of the start of proestrus (Goodwin et al, 1979). Females will remain non-receptive to mounting
by males during proestrus. This stage is usually 6-11 days in length, with an average of 9 days
(Feldman and Nelson, 2004).
The primary influencing hormone during proestrus is estrogen, which is synthesized and
secreted by the ovarian follicles (Feldman and Nelson, 2004). This has been demonstrated by
administering estrogens to ovariohysterectomized females, leading them into a state of proestrus
without vaginal bleeding (Concannon, 1987). Circulating estrogen concentrations in early
proestrus are typically above 25 pg/mL, while late proestrus normally are around 60-70 pg/mL
(Feldman and Nelson, 2004; Olson, 1982). Serum testosterone levels increase in the bitch in late
proestrus, typically obtaining concentrations of 0.3-1.0 ng/mL (Olson et al, 1984). Serum
progesterone concentrations throughout proestrus are low (< 0.5 ng/mL) except during the last
24-72 hours leading into estrus (Feldman and Nelson, 2004).
When performing ultrasonography in the bitch during proestrus, evaluation of the ovaries
will reveal a gradual increase in overall size due to follicular development. This will appear as
focal hypoechoic to anechoic rounded structures (Feldman and Nelson, 2004). Vaginoscopy will
reveal a thickened, well rounded, edematous, smooth, and shiny vaginal mucosa (Jeffcoate,
1988). Other changes associated with proestrus include growth of mammary gland ducts and
tubules, proliferation of oviductal fimbria, thickening of oviducts and endometrium, elongation
of uterine horns, increased myometrial sensitivity, enlargement of the cervix, and proliferation of
the vaginal wall (Concannon and DiGregorio, 1986; Concanon 1987). Vaginal cytology during
early proestrus often resembles that from a bitch in anestrus with numerous parabasal cells, small
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to large intermediate vaginal epithelial cells, neutrophils (± bacteria), and the presence of red
blood cells (Feldman and Nelson, 2004). Mid-proestrus typically will contain red blood cells,
and an increase in percentage of superficial cells replacing the smaller parabasal and
intermediate cells (Feldman and Nelson, 2004). Late proestrus generally will contain, decreased
number of red blood cells, with more than 80% of exfoliated superficial vaginal cells, with a
nucleus that is vesiculated or pyknotic (Feldman and Nelson, 2004).
Estrus generally is described as the stage during which the bitch allows the male to mount
and breed. The duration is usually between 5-9 days. Hormonal changes include a peak of
estrogen concentrations 24-48 hours prior to the onset of estrus, followed by decline of estrogen
and increase of concentrations of serum progesterone. These hormonal changes are vital for the
positive feedback between the hypothalamus and pituitary gland resulting in the secretion of the
follicle stimulating hormone (FSH) and the luteinizing hormone (LH) surge in early estrus
(Concannon, 1987). The LH surge initiates ovulation within 24-48 hours, after which the corpus
luteum forms (Feldman and Nelson, 2004). As the estrus stage progresses, serum progesterone
levels continue to rise, additionally doing so through several weeks of diestrus. Testosterone
concentrations obtain maximum levels at the time of both the preovulatory LH surge and
behavioral receptivity to males (Olsen et al, 1984).
Ultrasonography during estrus can reveal a decrease in the number of visible follicles, an
oval shape of the ovaries that becomes more rounded post ovulation, and the presence of cysticlike anechoic structures that are indistinguishable from follicles. These may represent
nonovulatory follicles, corpora hemorrhagica, fluid-filled copora lutea, or cystic luteinized
follicles (England and Allen, 1989; Wallace et al, 1992). All ovarian follicles are believed to
rupture within 12-96 hours (Jeffcoate, 1998). Throughout estrus the uterus is preparing for
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implantation. Vaginal bleeding has typically stopped at the start of the estrus phase and the
uterus can normally begin to be palpable during abdominal examination due to its increased size
and overall thickness. The vulva becomes soft and flaccid, allowing easy access for the male to
penetrate. Vaginal discharge is often reported as a straw-colored to pink fluid (Feldman and
Nelson, 2004). Vaginal cytology throughout standing (early estrus) includes >80% superficial
cells and anuclear squames with no neutrophils (Feldman and Nelson, 2004). Red blood cells
may be present on vaginal cytology. Vaginal endoscopy typically will reveal a reduction in
mucosal vascularity and edema, and the luminal surface of the vagina then becomes more
“crenulated” (Concannon, 1987). Crenulation is the development of angulated folds of vaginal
mucosa with sharp edges (Feldman and Nelson, 2004).
Diestrus is defined as the stage of progesterone dominance. It begins with the cessation of
standing heat and ends when concentrations of serum progesterone return to baseline levels,
typically < 1 ng/mL (Feldman and Nelson, 2004). During this phase, the bitch will abruptly
refuse to allow the male to breed. The duration of this stage is 56-58 days in the pregnant bitch
and 60-100 days in the nonpregnant bitch (Feldman and Nelson, 2004). Corpora lutea regression
is associated with the gradual decrease of serum progesterone concentration and changes to
vascular supply (Feldman and Nelson, 2004). Studies have reported the presence of lymphocytes
(e.g., CD4, CD8, MHCII-antigen expressing cells) within corpora lutea at early and late diestrus
(Hoffman et al., 2004) suggesting an immune-mediated response may also play a role in
regression of corpora lutea. Prolactin is also referenced as a key hormone of this stage in the
pregnant bitch. As progesterone decreases, prolactin concentrations increase in the late stages of
diestrus. Mammary enlargement and secretory activity during diestrus are presumed to be
initiated and maintained by prolactin, causing lactation in preparation for offspring (De Coster et
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al, 1983; Concannon, 1986). Prolactin is also required for luteal function in the dog (Concannon
et al. 1987). Administration of dopamine agonists induces significant declines in progesterone
and terminates luteal function (Concannon et al. 1987). Serum immunoreactive relaxin
concentrations differ between pregnant (>3.0 ng/mL) and non-pregnant dogs (<0.25 ng/mL)
approximately 6-7 weeks into gestation (Steinetz et al, 1989; Buff et al, 2000). Relaxin is
produced primarily by the placenta (Tsutsui and Stewart, 1991). The uterus is highly glandular
and vascular during diestrus. On vaginal cytology an abrupt change from superficial cells to
intermediate and parabasal cells is usually one of the first indicators of diestrus (Feldman and
Nelson, 2004).
Anestrus is the phase in which the bitch is in a state of “reproductive rest” and the uterus
involutes undergoing self-repair. It can be difficult to determine the start of anestrus in the nonpregnant bitch. Typically, this phase is considered to last an average of 4.5 months (Feldman and
Nelson, 2004). Complete repair of the endometrium to a basal state requires ~120 days after
decline of progesterone to basal levels in the non-pregnant dog and ~140 days after a fertile cycle
(Talwar et al, 1985; Johnston et al, 1985). Sporadic bursts of LH secretion and increases in FSH
can occur throughout anestrus in the bitch. Progesterone is extremely low during anestrus (<1
ng/mL), while estrogen concentrations significantly fluctuate (Feldman and Nelson, 2004).
Vaginal cytology in anestrus reveals parabasal and intermediate vaginal epithelial cells (±
neutrophils and bacteria).
1.2 Infertility in the Bitch
Understanding infertility in any species can be a daunting challenge. When confronted with
infertility in the bitch, several attributing factors must be considered. It is crucial for any
practicing veterinarian to obtain a thorough history of the bitch’s breeding and reproductive
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background. Additional questions to address include: the bitch’s environment, signalment, and
pre-existing health conditions. For instances, bitches housed together overtime may begin to
have a synchronous cycle inducing a condition referred to as “dormitory effect” (Johnston et al.,
2001). The most common reported cause of female infertility is the failure to perform proper
timed breeding (Feldman and Nelson, 2004; Johnston, 2001).
Abnormalities of the reproductive cycle that can cause infertility include persistent
anestrus or primary anestrus. This is a condition in which the bitch lacks having a normal
reproductive cycle by 2 years of age (Johnston, 1991). Primary causes for persistent anestrus in
an intact bitch include: silent heat, abnormalities of sexual differentiation, hypothyroidism, druginduced, systemic disease, ovarian cyst, ovarian aplasia, and immune-mediated oophoritis
(Johnston, 2001). Silent heat in the bitch is described as ovarian activity with no associated vulva
swelling, vulvar discharge, and/ or attraction of males (Johnston, 1991). This can be diagnosed
by frequent assessment of serum progesterone concentrations yielding results greater than 2
ng/mL and large percentages of cornified cells on vaginal cytology (Johnston, 1991). In one
study, 18 bitches with silent heat were successfully induced into estrus after treatment with FSH
injections given intramuscularly (IM) or subcutaneously (SC) (Arbeiter and Dreier, 1972).
Abnormalities of sexual differentiation involve abnormal chromosome complements and
karyotypes that may lead disorders of sex development, resulting in primary anestrus (Johnston,
1991; Bosu et al., 1978; Johnston et al., 1985). Hypothyroidism is one of the most common
endocrine disorders of dogs and is believed to cause infertility by interfering with gamete
maturation (Johnston, 1989). Granulosa cell function is supported by thyroid hormones and is
required for placental trophoblast function once conception has occurred (Johnson et al., 1997).
Approximately 75% of bitches with hyperadrenocorticism have reported persistent anestrus
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(Reimers, 1983). It is believed that elevated serum cortisol levels cause a reduction in LH
synthesis and secretion from the pituitary gland result in infertility (Kemppainen, 1983). LH is
also a hormone required for luteal function in the dog. Hypophysectomy leads to an immediate
decline in concentrations of blood progesterone and ends luteal function; whereas administration
of LH elevates blood progesterone (Concannon, 1980).
Bitches with other systemic diseases, such as renal azotemia and cancer (transmissible
venereal tumors, adenocarcinomas, leiomyomas), are less likely to cycle than normal bitches
(Johnston et al., 2001). Progesterone-secreting ovarian cyst can lead to a negative feedback to the
pituitary gland, decreasing gonadotropin release and preventing normal cycling (Johnston et al.,
2001). Ovarian aplasia is a rare congenital anomaly in the dog result of a defect in prenatal germ
cell migration, resulting in elevated serum gonadotropin levels (Johnston, 1989; Johnston, 1991).
Another reported rare causes of infertility in the bitch is oophoritis. This is described as the
diffuse infiltration of mononuclear inflammatory cells within the ovary, typically accompanied
by fibrosis of the surrounding tissues (Johnston, 1989; Andersen and Simpson, 1973; Nickel et
al. 1991). The cause is still unknown, but speculated to have an auto-immune pathogenesis.
Secondary anestrus is a condition described as prolongation of the interestrus interval. In the
bitch this may be caused by endocrinopathies such as hypothyroidism and hyperadrenocorticism
or luteal cyst that secretes progesterone (Kemppainen, 1983).
If a bitch has a combined proestrus and diestrus phase greater than 6 weeks, this is
defined as persistent estrus (Jeffcoate, 1991). Clinically these animals will present with a
persistent sanguineous vaginal discharge and prolonged attraction to males, leading to an
associated vaginitis (Freshman, 1991; Allen and Renton, 1982). Most commonly this is caused
by presence of ovarian granulosa cell tumors or follicular cysts; however, an association with
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hepatic portosystemic shunts, thought to alter metabolism of circulating hormones, and
idiopathic lymphocytic oophoritis have been reported (Johnston et al. 2001; Freshman, 1991;
Nickel et al., 1991).
Physical abnormalities to the reproductive tract and associated structures may also play a
role in infertility. The most common vaginal abnormality is typically circumferential strictures,
resulting in failure of natural copulation by the male penis (Wykes and Soderberg, 1983). Other
anatomic structural abnormalities that could result in infertility include vaginal prolapse,
hyperplasia. This is commonly seen in large (giant) breed bitches during proestrus and estrus and
will commonly reoccur (Johnston, 1989).
Uterine infections and other alterations must also be ruled out if infertility is suspected.
They can potentially create a harmful environment for both the sperm and egg. Common
pathogens to cause an infertile uterus include aerobic bacteria (Enterobacteriaceae, gram-positive
cocci), Brucella canis, canine herpesvirus, and Mycoplasma canis (Johnston et al. 2001). These
can lead to pyometra in the bitch and cause pregnancy loss or infertility. Another common
alteration of the uterus is cystic endometrial hyperplasia (CEH), leading to failure of
implantation post conception (Freshman, 1991). The breeding age of the bitch must also be
considered in causes of infertility. Dogs do not undergo a true cessation of the reproductive cycle
coinciding with old age, but a decrease in fertility is often seen in bitches great than 5 years of
age, typically with an increased interestrus interval (Johnston et al, 2001; Perkins and Thomas,
1993; Johnson et al., 1987). Other miscellaneous causes of infertility speculated in the literature
involve production of anti-sperm antibodies produced by the cervix in the bitch (Feldman and
Nelson, 2004). Male dogs infected with Brucella canis have also been reported to have antisperm antibodies (George and Carmichael, 1984). There is additionally one report of bitches
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producing anti-egg zona pellucida antibodies post immunization techniques with isolated and
solubilized swine or canine zonae pellucidae, resulting in an infertile female (Mahi-Brown et al,
1982).
Hypoluteoidism is also reported as a cause of infertility in the bitch. It is described as a
reproductive condition in which insufficient levels of endogenous progesterone are synthesized
and secreted by corpora lutea, resulting in failure to maintain a functional secretory endometrium
(Feldman and Nelson, 2004; Johnston et al., 2001). This condition can prevent normal embryo
implantation, development, and ultimately end in total loss of pregnancy. If serum levels fall less
than 2 ng/mL for greater than 48 hours, pregnancy can be lost (Feldman and Nelson, 2004;
Johnston et al., 2001). More recently, it has been reported that pregnant bitches that underwent
abortion between four and six weeks of gestation had a decrease in serum progesterone below 10
ng/mL beginning at the third week of pregnancy (Thuróczy et al., 2016). The etiology of
hypoluteoidism in the bitch is still not fully understood. Many have speculated this condition is
result of an associated gene mutation and poor breeding schemes (e.g., inbreeding), suggesting a
hereditary component. Others hypothesize a potential signaling defect between receptors within
the bitch reproductive tract and the hypothalamic-hypophyseal-gonadal axis, while others
propose an autoimmune response against progesterone (Dockweiler et al., 2017; Krachudel et al.,
2013). Studies investigating the correlation between preterm labor, myometrial activity, and
cervical changes as potential etiologies for hypoluteoidism are currently in progress (Davidson,
2015). Hypoluteoidism in the breeding bitch is relatively uncommon, but presently there are no
safe and effective therapies FDA-approved for use in the dog, indicating the need for further
scientific investigations.
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1.3 Current Medical Therapies for Treating Infertility in the Bitch
The treatment modality of choice for infertility in the bitch will depend primarily on the
suspected cause as previous discussed in section 1.2. It is vital that both a thorough history be
obtained and an extensive physical examination be performed using routine diagnostic
modalities. This will assist the clinician in ruling out any breeding management, infectious, or
non-infectious causes of infertility (Figure 1.1).

Figure 1.1. Common causes of infertility in the bitch.
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It is also important not to lose site of the relationship of the breeding male and its role in the
process of canine reproduction. Abnormalities within the male reproductive organs, decrease in
sperm production, abnormal sperm morphology, and infectious diseases can all decrease the
pregnancy rate in the bitch (Wilborn and Maxwell, 2012).
Even though significant advances have been made within the practice of small animal
reproduction, there is still a need for continued investigation into safe alternatives in treating the
numerous causes of infertility in the bitch. Current treatments include properly timed breeding
and management, hormonal therapy and replacement, assisted reproductive technology (i.e.
vaginal, transcervical, and surgical insemination), surgical intervention, and the use of antibiotics
when warranted (Feldman and Nelson, 2004; Johnston et al., 2001; Wilborn and Maxwell, 2012;
Chastant-Maillard, 2010). Alternative technologies using embryo transfer and intracytoplasmic
sperm injection are potential therapies; however, further investigation into developing protocols
are required. A recent study successfully reported the birth of seven healthy puppies after in
vitro-derived embryo transfer in beagles, suggesting an efficacious alternative in assisted
reproduction technology (Nagashima et al., 2015).
Medical induction of estrus has historically been used to treat infertility resulting from
prolonged inter-estrus intervals, and primary and secondary anestrus. This has been clinically
achieved by using commercially available equine chorionic gonadotropin (eCG) from pregnant
mares and human chorionic gonadotropin (hCG) from the urine of pregnant women (Feldman
and Nelson, 2004). eCG provides primarily an FSH-like action, stimulating initial follicular
development, and hCG has a similar effect to LH, serving as an initiator of ovulation (England,
1998). One study reported ovulation in ~50% of bitches after nine consecutive days receiving
intramuscular or subcutaneous administration of pregnant mare serum gonadotropin (PMSG).
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These subjects exhibited behavioral estrus 10-15 days after the start of treatment (Archbald et al,
1980). Another study using a combination of PMSG and hCG sequentially administered
subcutaneously resulted in excess serum concentration of estrogen levels causing several adverse
reactions including bone marrow suppression, failure of embryo implantation, and death
(England and Allen, 1991).
Protocols using FSH with or without estrogen priming have been described in the
literature. Estrogen pretreatment using diethylstilbestrol (DES) for 7 or more days has been
proven to successfully induce proestrus (Moses and Shille, 1988). This protocol followed by an
intramuscular injection of FSH, 9-11 days after the initial observation of vaginal bleeding,
resulted in pregnancy of all treated subjects (Moses and Shille, 1988); However, when using the
same protocol and replacing FSH with hCG the onset of behavioral estrus was significantly
decreased (Shille et al., 1989).
Protocols using gonadotropin-releasing hormone or GnRH agonist to induce a fertile
ovarian cycle have also been described. This of course can only take place with a normal intact
pituitary-ovarian axis. One protocol evaluated the use of a surgically implant infusion pump
releasing small amount of GnRH every 90 minutes for 6-12 days resulting in successfully
induction of proestrus, followed by fertile estrus (Vanderlip et al., 1987; Cain et al., 1988).
Historically these studies made significant advancements for new therapies, but the overall high
cost to use them made it inaccessible to practitioners (Feldman and Nelson, 2004). An alternative
therapy was then evaluated using subcutaneous injections of a GnRH agonist (deslorelin) three
times daily for 3 consecutive days. This resulted in the induction of estrus within 9-11 days post
starting the treatment in ~80% of subjects, each of which successfully became pregnant (Cain et
al, 1990). Another study used cabergoline, a dopamine receptor agonist, in 6 bitches diagnosed
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with primary or secondary anestrus. Five of the dogs resulted in normal proestrus and estrus,
which all were successfully bred and whelped normal litters with no adverse effects reported
(Gobello et al, 2002).
Other therapies for non-infectious causes of infertility in the bitch include the use of
synthetic progestins for diseases such as hypoluteoidism. There is currently no FDA-approved
source of progesterone for supplementation during pregnancy in the dog. Therapies for treating
hypoluteoidism in the bitch have presented unique challenges primarily because the definitive
cause of the condition is unknown, but the literature reports success using injectable and oral
(Regu-Mate®) synthetic progestins in bitches (Tsutsui, 1983; Purswell, 1991; Eilts et al., 1994).
Caution must be taken, however, with the use of synthetic progestins due to their numerous
reported adverse effects on the overall health of the bitch and the prevention of natural whelping
(Eilts et al., 1994; Maddison, 2008).
1.4 The Role of Progesterone in the Bitch
The endocrine system in the bitch plays a vital role in the regulation and ultimately success
of pregnancy in the domestic canine. The Beagle dog is currently the most common evaluated
breed as it pertains to the correlation between hormone profiles and pregnancy; however, a few
reports that have produced similar data have found no differences among other breeds (Johnston
et al. 2001; Concannon and Lein, 1989). Progesterone is considered to be the primary hormone
during pregnancy and the diestrus phase and is synthesized and secreted by the corpora lutea
within the ovary (Figure 1.2).
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Figure 1.2. Histology images representing the normal microscopic anatomy of the canine ovary:
(A) canine ovary with multiple corpora lutea. (B) Corpus luteum, 20x. (C) Tertiary follicle, 10x.
(D) Secondary follicles, 10x. FF=antrum filled with follicular fluid, CL=corpus luteum,
GC=granulosa cells, I=interstitial gland, TA=tunica albuginea, *=secondary follicles
Its secretion is heavily regulated by luteotropic and luteolytic parameters which is primarily
processed by the pituitary gland. Typically, 24-48 hours prior to parturition in the bitch there is a
gradual decline of serum progesterone concentrations (Feldman and Nelson, 2004; Johnston et
al., 2001). The decline of progesterone prior to parturition takes place coincidently with an
increase of prostaglandin F2a levels as result of cyclooxygenase 2 production in fetal trophoblast
(Kowalewski et al., 2010). It is generally assumed that plasma progesterone concentrations must
be ³ 2ng/mL to maintain pregnancy (Verstegen-Onclin and Verstegen, 2008). Progesterone
14

secures the differentiation of both the endometrium and endometrial gland secretion, and also
placental attachment (Verstegen-Onclin and Verstegen, 2008). Suppression of uterine
contractions is achieved as result of progesterone preventing uterogenic activity of estrogens
(Verstegen-Onclin and Verstegen, 2008).
There is no difference between pregnant and non-pregnant bitches in progesterone
concentrations during diestrus (Net et al., 1975; Reimers et al., 1978). Therefore, it cannot be
used as a sole indicator of pregnancy confirmation in the bitch. Concentrations levels of
progesterone in pseudopregnant bitches compared to pregnant animals is still under investigation
(Johnston et al. 2001). The number of corpora lutea should be equal to the number of fetuses
(Johnston et al, 2001). If there is not a similar correlation of fetus number within a horn and the
number of corpora lutea in the ipsilateral ovary, this may be the result of transuterine migration
of embryos (Shmizu et al., 1990).
There currently has never been a study to evaluate the total amount of progesterone secreted
by each corpora lutea amongst different breeds. There additionally has never been a study to
evaluate progesterone secreted by multiple corpora lutea in dogs that produce large litters
compared to smaller litters. We understand the importance of the role progesterone plays in the
bitch during gestation and we believe answering these previous questions will assist in not only
diagnosing, but treating hormonal related causes of infertility in the bitch. This is why our
laboratory is particularly interested in investigating safe alternatives to synthetic progestins and
evaluating the correlation between progesterone, the ovary, and the uterus.
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1.5 Objectives
The objective of this project was to evaluate the efficacy and safety of human-labeled
micronized progesterone therapies for use as an alternative treatment of hypoluteoidism in the
bitch.
Specific Aims
1. Utilize a dog model in anestrus to measure plasma progesterone concentrations in the bitch
after single administration of vaginally (Crinone®) and oral (Prometrium®) delivered micronized
progesterone.
2. Determine and compare the pharmacokinetics (PK) of vaginally (Crinone®) and orally
(Prometrium®) delivered micronized progesterone in the bitch. Data collected will be utilized to
devise therapeutic protocols for use in dogs at risk of hypoluteoidism and pregnancy failure.
Key pharmacokinetic parameters to determine will include area under the curve (AUC),
maximum plasma concentration (Cmax), time elapsed to reach Cmax (Tmax), and elimination halflife (t1/2).
3. Evaluate the most efficacious progesterone concentration and administration route that will be
capable of maintaining plasma progesterone levels above 1-2 ng/mL when given once daily.
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Chapter 2. Pharmacokinetics of Micronized Progesterone following Oral or
Intravaginal Administration in Female Dogs
2.1 Introduction
Progesterone is a vital hormone for both implantation and pregnancy maintenance in both
humans and animals. Progesterone secreted from the canine corpus luteum is needed throughout
the canine pregnancy until term. It is thought to be necessary for endometrial glandular
development, secretion of uterine fluids, endometrial growth, and maintenance of placental
attachments (Feldman and Nelson, 2004; Verstegen-Onclin and Verstegen, 2008).
Concentrations of plasma progesterone increase coincidentally with LH surge during early
estrus, peak at ~20-30d post the luteinizing hormone (LH) surge, and slowly decrease by 60 to
70 days of the non-pregnant diestrus or late pregnancy. Plasma progesterone levels must be ≥ 2
ng/mL to successfully maintain pregnancy in the bitch (Verstegen-Onclin and Verstegen, 2008).
Some dogs may experience frank abortion or fetal resorption as result of decreased plasma
progesterone concentrations, a phenomenon known as hypoluteoidism.
Hypoluteoidism, also referred to as luteal insufficiency in the literature, is a rising concern in
small animal theriogenology with limited treatment options (Practice Committee of the
American Society of Reproductive Medicine, 2015; Jones, 1949). It is described as a
reproductive condition in which insufficient progesterone is secreted by the corpora lutea
resulting in failure to maintain a functional secretory endometrium, thus preventing normal
embryo implantation, and development, ultimately ending in loss of pregnancy (Practice
Committee of the American Society of Reproductive Medicine, 2015; Johnston et al., 2001;
Görlinger, 2005).
Potential etiologies for the condition remain to be elucidated, but both primary and
secondary (e.g. pituitary defect) ovarian problems have been described (Hayer, 1997).
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The objective of this study was to determine the pharmacokinetics (PK) of vaginally
(Crinone®, Watson Laboratories, Inc., Salt Lake City, UT) and orally delivered micronized
progesterone (Prometrium®, AbbVie Inc, North Chicago, IL) in the bitch. Our primary focus was
to evaluate these progesterone formulations as a possible treatment for low plasma progesterone
levels as result of hypoluteoidism. Current synthetic progestins (i.e., medroxyprogesterone,
megestrol acetate, proligestone) available to treat bitches pose a risk to their uterine and overall
health. Side effects associated with progestin supplementation in dogs and humans include cystic
endometrial hyperplasia, mammary tissue dysplasia and potential development of metabolic
disorders (Practice Committee of the American Society of Reproductive Medicine, 2015;
Fitzpatrick and Good, 1999; Maddison et al., 2008).
Prometrium® and Crinone® are natural micronized progesterone supplements that are
currently used in women as a hormone supplement or replacement as part of an assisted
reproductive treatment. Prometrium® is available in both 100 mg and 200 mg capsules for oral
administration only. Crinone® is available as a 45 mg (4%) or 90 mg (8%) bio adhesive gel
emulsion system for intravaginal (IVa) administration. Hormones that are not water soluble,
such as progesterone, have poor absorption and poor bioavailability when administered orally.
Previously reported studies have verified that micronized preparations of progesterone yield
greater solubility when administered orally and resulted in fewer if no clinical side effects in
humans (Chaumeil, 1998). Micronized progesterone is bioidentical to the natural progesterone
produced by the corpus luteum, providing a safe alternative to synthetic progestins with
significantly less side effects, as it has been shown in women (Practice Committee of the
American Society of Reproductive Medicine, 2015; Fitzpatrick and Good, 1999).
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We hypothesized that both vaginal and oral treatments would result in a dose-dependent
increase in concentrations of plasma progesterone in the bitch. We further hypothesized that oral
dosing of micronized progesterone would result in greater, sustained, plasma progesterone
concentrations than would be seen with intravaginal micronized progesterone gel. Understanding
the half-life and clearance of micronized progesterone will enable practitioners to effectively
prescribe it for progestational support, as well as appropriate withdrawal prior to whelping.
2.2 Materials and Methods
Animals

The study protocol was approved by the Louisiana State University Institutional Animal
Care and Use Committee. The work was performed in an animal facility accredited by the United
States Department of Agriculture and AAALAC International, and assured by the Office of
Laboratory Animal Welfare in accordance with The Guide for the Care and Use of Laboratory
Animals (ILAR, 2011). A total of eight adult sexually intact female dogs were enrolled. All
bitches used were screened for any preexisting health conditions by thorough health record
evaluation, baseline complete blood counts (CBC), blood chemistries and urinalysis assessments.
To prevent interference from other medications a two-week wash out period was instituted prior
to the start of the study.
Experiment 1

Eight bitches in anestrus were arranged in a 4x4 Latin square cross over experimental design
(Table 2.1).
Table 2.1. Experimental Design: 4x4 Latin square cross over experimental design.
Animal #
1,2
3,4
5,6
7,8

Treatment 1
100 mg, PO
200 mg, PO
45 mg, IVa gel
90 mg, IVa gel

Treatment 2
200 mg, PO
100 mg, PO
90 mg, IVa gel
45 mg, IVa gel

Treatment 3
45 mg, IVa gel
90 mg, IVa gel
100 mg, PO
200 mg, PO

Treatment 4
90 mg, IVa gel
45 mg, IVa gel
200 mg, PO
100 mg, PO

Micronized progesterone; PO-oral administration using tablets of 100 or 200 mg;
IVa-intravaginal administration of progesterone bioadhesive gel at 4% and 8% strength to deliver
45 mg and 90 mg of micronized progesterone, respectively.
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Each subject rotated through four different progesterone treatment groups with a minimum
seven day-wash out period between treatments: 100 mg oral micronized progesterone, 200 mg
oral micronized progesterone, 45 mg intravaginal micronized progesterone and 90 mg
intravaginal micronized progesterone (Figures 2.1-2.4).

A

B
Figure 2.1. (A) Crinone® intravaginal bioadhesive gel applicator. (B) Prometrium® oral capsule.
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Figure 2.2. Oral administration of Prometrium® capsule.

Figure 2.3. Intravenous blood collection from cephalic catheter (18G x 1 ¼ in)
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Figure 2.4. (A) Parting the vulvar labia to introduce the intravaginal device. (B) Craniodorsal
deviation of Crinone® applicator into vagina. (C) Placing the applicator plunger to dispense
bioadhesive gel. (D) Bitch hindquarters are raised at a 45°angle for 5 minutes directly after
administration of Crinone® intravaginal gel.
Blood samples from each subject were obtained at time points 0, 0.5, 2, 1.5, 2, 4, 6, 8, 12,
24, 36, 48 and 72 hours following one initial dosing of each treatment. Subjects were fed a
standard laboratory diet (LabDiet® 5006, Land O’ Lakes, Inc., St. Louis, MO) 10 to 15 minutes
prior to administration of each respective progesterone treatment and maintained on routine daily
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feeding schedule throughout the study. Blood samples were collected with an 18 gauge x 1 inch
intravenous cephalic catheter (Sur-Vet®, Terumo Medical Corporation, Somerset, NJ),
transferred into 3-mL lithium heparinized plastic sterile tubes (BD Vacutainer®, Becton
Dickinson and Company, Franklin Lakes, NJ), and centrifuged for plasma separation for 10
minutes at 1520 g. Plasma samples were placed in duplicate cryotubes and stored at -20° C until
analyzed. Concentrations of plasma progesterone were determined by radioimmunoassay
(ImmuChem Double Antibody, 125I RIA Kit, MP Biomedicals, Costa Mesa, CA).
Experiment 2

After analyzing data from our first study, an additional pilot study was performed using 4
adult sexually intact bitches in anestrus. Our goal was to evaluate which micronized progesterone
formulation and route would best maintain plasma progesterone levels above 1-2 ng/mL when
given once daily. Subjects received one daily dose of the respective treatment groups every 24
hours for five days: oral 100 mg micronized progesterone, 200 mg oral micronized progesterone,
4% (45 mg) intravaginal micronized progesterone and 8% (90 mg) intravaginal micronized
progesterone. Only one dog was used for each of the four treatment groups. Serial blood
collection was then performed at the following time points during five consecutive days: 0
(baseline), 4, 12, 24, 28, 36, 48, 52, 60, 72, 76, 84, 96, 100, and 108 hours. Blood samples were
collected from 18 gauge x 1 inch intravenous cephalic catheter (Sur-Vet®, Terumo Medical
Corporation, Somerset, NJ), transferred into 3-mL lithium heparinized plastic sterile tubes (BD
Vacutainer®, Becton Dickinson and Company, Franklin Lakes, NJ), and centrifuged for plasma
separation for 10 minutes at 1520 g. Plasma samples were placed in duplicate cryotubes and
stored at -20° C until analyzed. Concentrations of plasma progesterone were determined by
fluorescence enzyme immunoassay using an Automated Immunoassay Analyzer (AIA-360,
Tosoh Bioscience, Inc., San Francisco, CA).
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2.3 Results
Pharmacokinetic analysis was carried out using commercially available software (Phoenix
WinNonlin 6.4, Certara Inc., Princeton, NJ). One-compartmental (intravaginal) and noncompartmental (oral administration) modeling were performed to analyze data using the mean
concentrations for each dosing to calculate the area under the curve (AUC), maximum plasma
concentration (Cmax), time elapsed to reach Cmax (Tmax), and elimination half-life ( t1/2).
Results for the 100 mg and 200 mg oral doses and 45 mg and 90 mg IVa doses were as follows:
AUC, 30.86, 187.96, 90.64, and 226.68 ng.h.mL-1, respectively; Cmax, 13.47, 169, 8.68, and
13.24 ng.mL-1, respectively; Tmax, 0.5, 0.5, 0.84, and 1.67 h, respectively, and half-life, 5.87,
6.76, 6.6, and 10.65 h, respectively (Table 2.2).
Table 2.2. Pharmacokinetics of oral and intravaginal (IVa) micronized progesterone administered
to eight anestrus dogs.
Pharmacokinetics parameters
AUC (ng.h.mL-1)
Cmax (ng.mL-1)
Tmax (hr)
Half-life (hr)

100 mg oral
30.86
13.47
0.5
5.87

200 mg oral
187.96
169
0.5
6.76

45 mg IVa
90.64
8.68
0.84
6.6

90 mg IVa
226.68
13.24
1.67
10.65

Pharmacokinetic analysis was carried out using commercially available software (Phoenix
WinNonlin 6.4, Certara Inc., Princeton, NJ). One-compartmental (intravaginal) and noncompartmental (oral administration) modeling were performed to analyze data using the mean
concentrations for each dosing to calculate the area under the curve (AUC), maximum plasma
concentration (Cmax), time elapsed to reach Cmax (Tmax), and elimination half-life ( t1/2).
No adverse reactions were seen during the entire duration of the both experiments.
Progesterone exposure over time, as indicated by the area under the curve, was greater when
intravaginal micronized progesterone was used (Table 2.2). There was no present “carry over”
effect amongst treatment groups, validating the efficacy of the seven-day washout period. Figure
2.7 distinctly supports this argument showing that by the 72 h mark, all treatment groups have
return to baseline levels, also verifying each subject was maintained in the anestrus phase of their
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reproductive cycle. Furthermore, baseline concentrations of plasma progesterone were confirmed
immediately before the start of subsequent treatments throughout the study.
Micronized progesterone delivered orally or intravaginally was readily absorbed in bitches
following a single or daily dose treatment (Figures 2.5-2.7).

Figure 2.5. Line graph comparing concentrations of plasma progesterone over time (72 hours)
after a single administration of micronized progesterone. The dashed line represents target value
to maintain plasma progesterone levels above 1 ng/mL with micronized progesterone therapy.
PO-oral; IVa-intravaginal.
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Figure 2.6. Box and whisker plot (at 24 hours) after a single administration of micronized
progesterone. The dashed line represents target value to maintain plasma progesterone levels
above 1 ng/mL with micronized progesterone therapy. PO-oral; IVa-intravaginal.
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Figure 2.7. Line graph showing concentrations of plasma progesterone following administration
of micronized progesterone given once daily for five days. The dashed line represents target
value to maintain plasma progesterone levels above 1 ng/mL with micronized progesterone
therapy. PO-orally; IVa-intravaginally.
Experiment 1 revealed that intravaginal formulations successfully maintained plasma
progesterone levels ≥ 1 ng/mL for 24 hours (Figure 2.6). The oral progesterone formulations
yielded the greatest values, but fell below 1 ng/mL between 12-24 hours. Concentrations of
plasma progesterone returned to pre-treatment levels by 72 hours (Figure 2.5). Experiment 2
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revealed that intravaginal formulations given once daily successfully maintained plasma
progesterone levels ≥1 ng/mL for the duration of the experiment (5 days; 120 hours).
Concentrations of plasma progesterone returned to pre-treatment levels 72 hours after the final
daily dose was administered (Figure 2.7). No adverse reactions were seen during the entire
duration of the study. Additionally, blood chemistry panels performed before and after the study
revealed no significant findings
2.4 Discussion
Hypoluteoidism is a reproductive condition in which insufficient levels of endogenous
progesterone are synthesized and secreted by the corpus luteum. Whereas true hypoluteoidism in
bitches during pregnancy is relatively uncommon, declining concentrations of blood
progesterone normally seen during canine late gestation may raise concerns for dog breeders and
veterinarians, especially if patients have experienced infertility or pregnancy losses in the past.
Low (< 5 ng/mL) or declining blood levels of progesterone may prompt veterinarians to
prescribe progesterone supplementation. Pre-natal examinations have grown popular among dog
breeders where they often request multiple ultrasound examinations to determine fetal wellbeing. In addition, in bitches with a history of infertility, determination of concentrations of
blood progesterone is often performed. Pregnant bitches that present with fluctuating,
consistently declining, or overall low plasma progesterone levels prompt clinicians to prescribe
progesterone supplementation. This approach is warranted as bitches with a pattern of declining
blood progesterone levels may be at risk for infertility and pregnancy loss. There are several case
reports where hypoluteoidism has been diagnosed in dogs because clinicians were unable to
definitively identify any other common pathogens that cause infertility and abortion in the bitch
(Görlinger et al., 2005; Hayer, 1997; Root Kustritz, 2001; Purswell, 1991; Estill, 1998; Johnson,
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2008; Günzel-Apel et al., 2012; Tibold and Thuróczy, 2009). The etiology of hypoluteoidism in
the bitch is still not fully understood. Many have speculated this condition is result of an
associated gene mutation and poor breeding schemes (i.e., inbreeding), indicating a hereditary
component. Others hypothesize a potential signaling defect between receptors within the bitch
reproductive tract and the hypothalamic-hypophyseal-gonadal axis (Dockweiler et al., 2017;
Krachudel et al., 2013). Further studies are needed to fully characterize hypoluteoidism in the
dog.
There is currently no FDA-approved source of progesterone for supplementation during
pregnancy in the dog. There are a few reports of injectable (oil based) progesterone preparations
that have been used in the anestrus and ovariectomized pregnant dog model yielding positive
results (Tsutsui, 1983; Scott-Moncrieff et al., 1990; Eilts et al., 1994). The most recent case
reports described in the literature have empirically used either oral (i.e., medroxyprogesterone
acetate, 0.1 mg/kg, PO SID and altrenogest, 0.088 mg/kg PO SID) or injectable (in oil) synthetic
progestogen and natural progesterone (Luteosan®; Alvetra and Werfft AG, Vienna, Austria) to
treat hypoluteoidism (Root Kustritz, 2001; Purswell, 1991; Estill, 1998; Johnson, 2008; GünzelApel et al., 2012; Tibold and Thuróczy, 2009). These therapies allowed the bitch to give birth to
viable puppies, after multiple failed attempts of breeding. Though these reports revealed
successful outcomes, current synthetic progestins available to treat dogs pose significant risk to
the reproductive tract and the overall health of the bitch. Many adverse effects associated with
synthetic progestin use have been reported and include: cystic endometrial hyperplasia,
mammary dysplasia, development of metabolic disorders (i.e. diabetes mellitus), masculinization
of female fetuses, and prevention of spontaneous parturition (Practice Committee of the

34

American Society of Reproductive Medicine, 2015; Fitzpatrick and Good, 1999; Maddison et al.,
2008).
To our knowledge, this is the first reported study to investigate the pharmacokinetics of
micronized progesterone in the bitch. The progesterone used in these products are extracted from
a plant root and as such are labeled as a natural product. The progesterone in Crinone® and
Prometrium® is converted from diosgenin (extracted from wild yams, Dioscorea spp) to
progesterone using standard laboratory techniques (Applexweig, 1969). The chemical formula
and associated structure (C21H30O2) for both Crinone® and Prometrium® are identical to that of
endogenous progesterone produced by the corpus luteum. They also possess the same molecular
weight; 314.5 g/mol (Crinone, 2014; Prometrium, 2013). Historically, progesterone given orally
was considered unfeasible due to its poor absorption; however, studies have now shown that this
can be improved with the appropriate vehicle and particle size (Hargrove et al., 1989).
Micronized progesterone formulations possess two major benefits: (1) increased bioavailability
with oral use and (2) significantly decreased adverse effects for both short and long term use,
compared to synthetic progestogens (Chaumeil, 1998; Hargrove et al., 1989; de Lignieres, 1999).
Progesterone is metabolized primarily by the liver and excreted by the kidney.
The ability of intravaginal preparations of micronized progesterone to induce sustained
progesterone exposure may provide an alternative strategy for treating pregnant dogs whenever
hypoluteoidism is being suspected. We propose that the longer half-life of the intravaginal
product is a result of bypassing first pass metabolism in the liver, as well as a slower absorption
rate. This same phenomenon termed “first uterine pass effect” has previously been described in
women treated with vaginally administered micronized progesterone (Bulletti et al., 1997;
Levine and Watson, 2000). Similar findings have been documented in women after vaginal use
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of drugs such as terbutaline and danazol (Kullander and Syanberg, 1985; Misutani et al., 1995).
Further investigation is warranted for both the oral and intravaginal preparations in pregnant
dogs to evaluate efficacy, safety, and to determine the optimum time to stop supplementation
prior to whelping. Additionally, alternative strategies to avoid first-pass prehaptic and hepatic
metabolism such as vaginally administered suppositories should be considered.
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Chapter 3. Conclusions
The intent of our study was to determine if the use of micronized progesterone will indeed
have a positive effect on the bitch and increase the plasma progesterone levels during anestrus.
After establishing this to be true, we set out to determine through a pilot study which route and
concentration may be efficacious in maintaining plasma progesterone levels above 1-2 ng/mL.
Our initial hypothesis was discovered to be invalid. Intravaginal micronized progesterone was a
more effective method than oral administration in the anestrus bitch in both experiments (figures
2.5-2.7).
Our findings raise many questions about variables that pertain to owner compliance. We
suspect that adequate training would be required in order to assist owners in becoming
comfortable with using the Crinone® gel applicator device. This is why initially the concept of
using oral micronized progesterone was appealing. We were unable to extensively evaluate any
toxic effects of micronized progesterone use in the bitch. Additionally, we were limited in our
sample size, and therefore strongly encourage further studies evaluating a similar protocol in a
larger population of bitches. It also would be interesting to evaluate the effects of micronized
progesterone in bitches in diestrus and complete a retrospective study of clinical cases in small
animal hospitals.
If progesterone levels fall below 2 ng/mL for more than 48 hours during pregnancy it is
often terminated (Johnston et al., 2001). Thus the need to discover safe alternatives for treating
hypoluteoidism in the bitch as most synthetic progestins pose significant risk to the bitch’s
health. Our study was originally adapted from the protocols used in women comparing
pharmacokinetics of Crinone® and Prometrium® in postmenopausal subjects (Levine and Watson
et al., 2000; Simon et al., 1993). Other concepts to explore involve developing technologies to
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produce slow-releasing injectable drugs or surgically placed osmotic pumps to deliver effective
doses of micronized progesterone over time. In future investigations of alternative therapies for
infertility in the bitch, it may be judicious to continue to integrate techniques used in other
mammalian species and human reproductive medicine.
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